Lv6
1780 积分 2020-10-26 加入
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
16天前
已完结
Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany
1个月前
已完结
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
1个月前
已完结
Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
2个月前
已完结
Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review
2个月前
已完结
Effects of repeated weight cycling on non‐alcoholic steatohepatitis in diet‐induced obese mice
2个月前
已完结
Weight loss and body composition after compounded semaglutide treatment in a real world setting
2个月前
已完结
Short‐term outcomes of switching from GLP‐1 receptor agonists to tirzepatide in type 2 diabetes: A retrospective, observational study in clinical practice
2个月前
已完结
The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis
3个月前
已完结
Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?
3个月前
已完结
皖公网安备34019202002308
